Go to content
UR Home

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

URN to cite this document:
DOI to cite this document:
Glutsch, Valerie ; Kneitz, Hermann ; Gesierich, Anja ; Goebeler, Matthias ; Haferkamp, Sebastian ; Becker, Jürgen C. ; Ugurel, Selma ; Schilling, Bastian
[img]License: Creative Commons Attribution 4.0
PDF - Published Version
Date of publication of this fulltext: 29 Feb 2024 12:35


Background Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis. In Europe, approved systemic therapies are limited to the PD-L1 inhibitor avelumab. For avelumab-refractory patients, efficient and safe treatment options are lacking. Methods At three different sites in Germany, clinical and molecular data of patients with metastatic MCC ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons